Loading…

Pre-existing Immunity and Passive Immunity to Adenovirus 5 Prevents Toxicity Caused by an Oncolytic Adenovirus Vector in the Syrian Hamster Model

We have used Syrian hamsters to examine the role of pre-existing immunity to adenovirus (Ad) 5 in the toxicity of the oncolytic Ad vector INGN 007. Groups of hamsters were or were not immunized with Ad5. Half the hamsters were immunosuppressed using cyclophosphamide (CP), then injected intravenously...

Full description

Saved in:
Bibliographic Details
Published in:Molecular therapy 2009-10, Vol.17 (10), p.1724-1732
Main Authors: Dhar, Debanjan, Spencer, Jacqueline F, Toth, Karoly, Wold, William SM
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c544t-338403419448f62bddb03754c031ad7441fe9bc72cdd004cbcffa6ddc19cd4313
cites cdi_FETCH-LOGICAL-c544t-338403419448f62bddb03754c031ad7441fe9bc72cdd004cbcffa6ddc19cd4313
container_end_page 1732
container_issue 10
container_start_page 1724
container_title Molecular therapy
container_volume 17
creator Dhar, Debanjan
Spencer, Jacqueline F
Toth, Karoly
Wold, William SM
description We have used Syrian hamsters to examine the role of pre-existing immunity to adenovirus (Ad) 5 in the toxicity of the oncolytic Ad vector INGN 007. Groups of hamsters were or were not immunized with Ad5. Half the hamsters were immunosuppressed using cyclophosphamide (CP), then injected intravenously (i.v.) with 3× the maximum tolerated dose (MTD) of INGN 007 (in immunocompetent hamsters), and toxicity and vector replication in the liver were quantitated. In nonimmunized immunocompetent hamsters, toxicity was observed early but the hamsters recovered by day 6 after vector injection. In nonimmunized immunosuppressed hamsters, the vector was lethal by 3 days. Pre-existing neutralizing antibody (NAb) prevented liver infection and hepatotoxicity in both immunocompetent and immunosuppressed hamsters. In another study, passive immunization of immunosuppressed hamsters 1 day before a lethal dose (1× MTD) of INGN 007 prevented liver infection and replication, but immunization 1 day after vector administration was barely effective. When immunosuppressed hamsters were passively immunized 1 day after injection of 1/3rd the MTD of INGN 007, then significant protection was observed against liver infection and toxicity. Therefore, serum NAb are sufficient to prevent oncolytic Ad vector liver infection and toxicity. We saw no evidence that pre-existing immunity was associated with increased vector toxicity.
doi_str_mv 10.1038/mt.2009.156
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2835003</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1525001616321360</els_id><sourcerecordid>4072869381</sourcerecordid><originalsourceid>FETCH-LOGICAL-c544t-338403419448f62bddb03754c031ad7441fe9bc72cdd004cbcffa6ddc19cd4313</originalsourceid><addsrcrecordid>eNptkVFrFDEQx4MotlaffNeAj7Jnskn2Ni9COdQWKi1YfQ3ZZLZNuU1qkl16H8NvbJY9rhV8mmHym_9M5o_QW0pWlLD205BXNSFyRUXzDB1TUYuKkJo_P-S0OUKvUrorGRWyeYmOqGxILWV7jP5cRajgwaXs_A0-H4bRu7zD2lt8pVNyEzwWc8CnFnyYXBwTFri0TuBzwtfhwZmZ2OgxgcXdLIAvvQnbXXbmadcvMDlE7DzOt4B_7KIr5JkeUoaIvwcL29foRa-3Cd7s4wn6-fXL9easurj8dr45vaiM4DxXjLWcME4l523f1J21HWFrwQ1hVNs157QH2Zl1bawlhJvO9L1urDVUGssZZSfo86J7P3YDWFN-EvVW3Uc36LhTQTv174t3t-omTKpumSCEFYEPe4EYfo-QsroLY_RlZ0XXshatbBkp1MeFMjGkFKE_TKBEzf6pIavZP1X8K_S7p0s9snvDCvB-AbzOY4QDMORZY5EQCwHleJODqJJx4A1YF8vxlQ3uv6P_AioItgg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1792589830</pqid></control><display><type>article</type><title>Pre-existing Immunity and Passive Immunity to Adenovirus 5 Prevents Toxicity Caused by an Oncolytic Adenovirus Vector in the Syrian Hamster Model</title><source>Open Access: PubMed Central</source><creator>Dhar, Debanjan ; Spencer, Jacqueline F ; Toth, Karoly ; Wold, William SM</creator><creatorcontrib>Dhar, Debanjan ; Spencer, Jacqueline F ; Toth, Karoly ; Wold, William SM</creatorcontrib><description>We have used Syrian hamsters to examine the role of pre-existing immunity to adenovirus (Ad) 5 in the toxicity of the oncolytic Ad vector INGN 007. Groups of hamsters were or were not immunized with Ad5. Half the hamsters were immunosuppressed using cyclophosphamide (CP), then injected intravenously (i.v.) with 3× the maximum tolerated dose (MTD) of INGN 007 (in immunocompetent hamsters), and toxicity and vector replication in the liver were quantitated. In nonimmunized immunocompetent hamsters, toxicity was observed early but the hamsters recovered by day 6 after vector injection. In nonimmunized immunosuppressed hamsters, the vector was lethal by 3 days. Pre-existing neutralizing antibody (NAb) prevented liver infection and hepatotoxicity in both immunocompetent and immunosuppressed hamsters. In another study, passive immunization of immunosuppressed hamsters 1 day before a lethal dose (1× MTD) of INGN 007 prevented liver infection and replication, but immunization 1 day after vector administration was barely effective. When immunosuppressed hamsters were passively immunized 1 day after injection of 1/3rd the MTD of INGN 007, then significant protection was observed against liver infection and toxicity. Therefore, serum NAb are sufficient to prevent oncolytic Ad vector liver infection and toxicity. We saw no evidence that pre-existing immunity was associated with increased vector toxicity.</description><identifier>ISSN: 1525-0016</identifier><identifier>EISSN: 1525-0024</identifier><identifier>DOI: 10.1038/mt.2009.156</identifier><identifier>PMID: 19602998</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adenoviridae - immunology ; Adenoviruses ; Animals ; Antibodies ; Antibodies, Neutralizing - immunology ; Cancer therapies ; Chemotherapy ; Clinical trials ; Cricetinae ; Cyclophosphamide - pharmacology ; Drug dosages ; Female ; Genes ; Genetic Vectors - immunology ; Genetic Vectors - toxicity ; Immunity - drug effects ; Immunity - physiology ; Immunocompetence ; Immunology ; Immunosuppressive Agents - pharmacology ; Infections ; Leukocytes ; Liver ; Liver - drug effects ; Liver - metabolism ; Mesocricetus ; Oncolytic Virotherapy - adverse effects ; Oncolytic Virotherapy - methods ; Original ; Toxicity ; Tumors ; Viruses</subject><ispartof>Molecular therapy, 2009-10, Vol.17 (10), p.1724-1732</ispartof><rights>2009 The American Society of Gene &amp; Cell Therapy</rights><rights>Copyright Nature Publishing Group Oct 2009</rights><rights>Copyright 2009, The American Society of Gene &amp; Cell Therapy 2009 The American Society of Gene &amp; Cell Therapy</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c544t-338403419448f62bddb03754c031ad7441fe9bc72cdd004cbcffa6ddc19cd4313</citedby><cites>FETCH-LOGICAL-c544t-338403419448f62bddb03754c031ad7441fe9bc72cdd004cbcffa6ddc19cd4313</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2835003/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2835003/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19602998$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dhar, Debanjan</creatorcontrib><creatorcontrib>Spencer, Jacqueline F</creatorcontrib><creatorcontrib>Toth, Karoly</creatorcontrib><creatorcontrib>Wold, William SM</creatorcontrib><title>Pre-existing Immunity and Passive Immunity to Adenovirus 5 Prevents Toxicity Caused by an Oncolytic Adenovirus Vector in the Syrian Hamster Model</title><title>Molecular therapy</title><addtitle>Mol Ther</addtitle><description>We have used Syrian hamsters to examine the role of pre-existing immunity to adenovirus (Ad) 5 in the toxicity of the oncolytic Ad vector INGN 007. Groups of hamsters were or were not immunized with Ad5. Half the hamsters were immunosuppressed using cyclophosphamide (CP), then injected intravenously (i.v.) with 3× the maximum tolerated dose (MTD) of INGN 007 (in immunocompetent hamsters), and toxicity and vector replication in the liver were quantitated. In nonimmunized immunocompetent hamsters, toxicity was observed early but the hamsters recovered by day 6 after vector injection. In nonimmunized immunosuppressed hamsters, the vector was lethal by 3 days. Pre-existing neutralizing antibody (NAb) prevented liver infection and hepatotoxicity in both immunocompetent and immunosuppressed hamsters. In another study, passive immunization of immunosuppressed hamsters 1 day before a lethal dose (1× MTD) of INGN 007 prevented liver infection and replication, but immunization 1 day after vector administration was barely effective. When immunosuppressed hamsters were passively immunized 1 day after injection of 1/3rd the MTD of INGN 007, then significant protection was observed against liver infection and toxicity. Therefore, serum NAb are sufficient to prevent oncolytic Ad vector liver infection and toxicity. We saw no evidence that pre-existing immunity was associated with increased vector toxicity.</description><subject>Adenoviridae - immunology</subject><subject>Adenoviruses</subject><subject>Animals</subject><subject>Antibodies</subject><subject>Antibodies, Neutralizing - immunology</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Cricetinae</subject><subject>Cyclophosphamide - pharmacology</subject><subject>Drug dosages</subject><subject>Female</subject><subject>Genes</subject><subject>Genetic Vectors - immunology</subject><subject>Genetic Vectors - toxicity</subject><subject>Immunity - drug effects</subject><subject>Immunity - physiology</subject><subject>Immunocompetence</subject><subject>Immunology</subject><subject>Immunosuppressive Agents - pharmacology</subject><subject>Infections</subject><subject>Leukocytes</subject><subject>Liver</subject><subject>Liver - drug effects</subject><subject>Liver - metabolism</subject><subject>Mesocricetus</subject><subject>Oncolytic Virotherapy - adverse effects</subject><subject>Oncolytic Virotherapy - methods</subject><subject>Original</subject><subject>Toxicity</subject><subject>Tumors</subject><subject>Viruses</subject><issn>1525-0016</issn><issn>1525-0024</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNptkVFrFDEQx4MotlaffNeAj7Jnskn2Ni9COdQWKi1YfQ3ZZLZNuU1qkl16H8NvbJY9rhV8mmHym_9M5o_QW0pWlLD205BXNSFyRUXzDB1TUYuKkJo_P-S0OUKvUrorGRWyeYmOqGxILWV7jP5cRajgwaXs_A0-H4bRu7zD2lt8pVNyEzwWc8CnFnyYXBwTFri0TuBzwtfhwZmZ2OgxgcXdLIAvvQnbXXbmadcvMDlE7DzOt4B_7KIr5JkeUoaIvwcL29foRa-3Cd7s4wn6-fXL9easurj8dr45vaiM4DxXjLWcME4l523f1J21HWFrwQ1hVNs157QH2Zl1bawlhJvO9L1urDVUGssZZSfo86J7P3YDWFN-EvVW3Uc36LhTQTv174t3t-omTKpumSCEFYEPe4EYfo-QsroLY_RlZ0XXshatbBkp1MeFMjGkFKE_TKBEzf6pIavZP1X8K_S7p0s9snvDCvB-AbzOY4QDMORZY5EQCwHleJODqJJx4A1YF8vxlQ3uv6P_AioItgg</recordid><startdate>20091001</startdate><enddate>20091001</enddate><creator>Dhar, Debanjan</creator><creator>Spencer, Jacqueline F</creator><creator>Toth, Karoly</creator><creator>Wold, William SM</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><general>Nature Publishing Group</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20091001</creationdate><title>Pre-existing Immunity and Passive Immunity to Adenovirus 5 Prevents Toxicity Caused by an Oncolytic Adenovirus Vector in the Syrian Hamster Model</title><author>Dhar, Debanjan ; Spencer, Jacqueline F ; Toth, Karoly ; Wold, William SM</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c544t-338403419448f62bddb03754c031ad7441fe9bc72cdd004cbcffa6ddc19cd4313</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adenoviridae - immunology</topic><topic>Adenoviruses</topic><topic>Animals</topic><topic>Antibodies</topic><topic>Antibodies, Neutralizing - immunology</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Cricetinae</topic><topic>Cyclophosphamide - pharmacology</topic><topic>Drug dosages</topic><topic>Female</topic><topic>Genes</topic><topic>Genetic Vectors - immunology</topic><topic>Genetic Vectors - toxicity</topic><topic>Immunity - drug effects</topic><topic>Immunity - physiology</topic><topic>Immunocompetence</topic><topic>Immunology</topic><topic>Immunosuppressive Agents - pharmacology</topic><topic>Infections</topic><topic>Leukocytes</topic><topic>Liver</topic><topic>Liver - drug effects</topic><topic>Liver - metabolism</topic><topic>Mesocricetus</topic><topic>Oncolytic Virotherapy - adverse effects</topic><topic>Oncolytic Virotherapy - methods</topic><topic>Original</topic><topic>Toxicity</topic><topic>Tumors</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dhar, Debanjan</creatorcontrib><creatorcontrib>Spencer, Jacqueline F</creatorcontrib><creatorcontrib>Toth, Karoly</creatorcontrib><creatorcontrib>Wold, William SM</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Molecular therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dhar, Debanjan</au><au>Spencer, Jacqueline F</au><au>Toth, Karoly</au><au>Wold, William SM</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pre-existing Immunity and Passive Immunity to Adenovirus 5 Prevents Toxicity Caused by an Oncolytic Adenovirus Vector in the Syrian Hamster Model</atitle><jtitle>Molecular therapy</jtitle><addtitle>Mol Ther</addtitle><date>2009-10-01</date><risdate>2009</risdate><volume>17</volume><issue>10</issue><spage>1724</spage><epage>1732</epage><pages>1724-1732</pages><issn>1525-0016</issn><eissn>1525-0024</eissn><abstract>We have used Syrian hamsters to examine the role of pre-existing immunity to adenovirus (Ad) 5 in the toxicity of the oncolytic Ad vector INGN 007. Groups of hamsters were or were not immunized with Ad5. Half the hamsters were immunosuppressed using cyclophosphamide (CP), then injected intravenously (i.v.) with 3× the maximum tolerated dose (MTD) of INGN 007 (in immunocompetent hamsters), and toxicity and vector replication in the liver were quantitated. In nonimmunized immunocompetent hamsters, toxicity was observed early but the hamsters recovered by day 6 after vector injection. In nonimmunized immunosuppressed hamsters, the vector was lethal by 3 days. Pre-existing neutralizing antibody (NAb) prevented liver infection and hepatotoxicity in both immunocompetent and immunosuppressed hamsters. In another study, passive immunization of immunosuppressed hamsters 1 day before a lethal dose (1× MTD) of INGN 007 prevented liver infection and replication, but immunization 1 day after vector administration was barely effective. When immunosuppressed hamsters were passively immunized 1 day after injection of 1/3rd the MTD of INGN 007, then significant protection was observed against liver infection and toxicity. Therefore, serum NAb are sufficient to prevent oncolytic Ad vector liver infection and toxicity. We saw no evidence that pre-existing immunity was associated with increased vector toxicity.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>19602998</pmid><doi>10.1038/mt.2009.156</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1525-0016
ispartof Molecular therapy, 2009-10, Vol.17 (10), p.1724-1732
issn 1525-0016
1525-0024
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2835003
source Open Access: PubMed Central
subjects Adenoviridae - immunology
Adenoviruses
Animals
Antibodies
Antibodies, Neutralizing - immunology
Cancer therapies
Chemotherapy
Clinical trials
Cricetinae
Cyclophosphamide - pharmacology
Drug dosages
Female
Genes
Genetic Vectors - immunology
Genetic Vectors - toxicity
Immunity - drug effects
Immunity - physiology
Immunocompetence
Immunology
Immunosuppressive Agents - pharmacology
Infections
Leukocytes
Liver
Liver - drug effects
Liver - metabolism
Mesocricetus
Oncolytic Virotherapy - adverse effects
Oncolytic Virotherapy - methods
Original
Toxicity
Tumors
Viruses
title Pre-existing Immunity and Passive Immunity to Adenovirus 5 Prevents Toxicity Caused by an Oncolytic Adenovirus Vector in the Syrian Hamster Model
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T08%3A36%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pre-existing%20Immunity%20and%20Passive%20Immunity%20to%20Adenovirus%205%20Prevents%20Toxicity%20Caused%20by%20an%20Oncolytic%20Adenovirus%20Vector%20in%20the%20Syrian%20Hamster%20Model&rft.jtitle=Molecular%20therapy&rft.au=Dhar,%20Debanjan&rft.date=2009-10-01&rft.volume=17&rft.issue=10&rft.spage=1724&rft.epage=1732&rft.pages=1724-1732&rft.issn=1525-0016&rft.eissn=1525-0024&rft_id=info:doi/10.1038/mt.2009.156&rft_dat=%3Cproquest_pubme%3E4072869381%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c544t-338403419448f62bddb03754c031ad7441fe9bc72cdd004cbcffa6ddc19cd4313%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1792589830&rft_id=info:pmid/19602998&rfr_iscdi=true